WNK2

WNK2 is a with-no-lysine (K) serine/threonine kinase within the mammalian WNK1-4 family, whose members regulate ion homeostasis, cell volume, epithelial transport, and cancer-related signaling^[1]. Mechanistically, WNK isoforms signal through SPAK/OSR1 and cation-chloride cotransporters, while full-length WNK2 can directly phosphorylate WNK1 Ser382 in vitro, supporting isoform cross-regulation by T-loop trans-autophosphorylation^[2]. In glioma models, WNK2 is recurrently silenced by promoter methylation, shows autophosphorylation and kinase activity enhanced by hypertonic conditions, and suppresses glioma colony formation in a kinase-independent manner^[3]. In meningioma, WNK2 CpG-island methylation occurs frequently in grade II-III tumors, associates with decreased expression, and methylation-inhibitor treatment can reactivate WNK2 expression in a methylated meningioma cell line^[4]. In glioma cells lacking WNK2, increased JNK activation, MMP2 expression, and MMP2 activity link WNK2 loss to invasion-relevant matrix remodeling^[5]. Compared with WNK1 and WNK4, which have established roles in inherited hypertension, WNK2 evidence more strongly centers on tumor suppressor biology, epigenetic silencing, MAPK/JNK signaling, and glioma or meningioma experimental models^[1][3][4][5]. WNK2-focused inhibitor or agonist applications remain insufficiently defined in these retrieved studies.